A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
- Conditions
- Advanced Solid Tumors
- Interventions
- Drug: Anti-PD-1 monoclonal antibody
- Registration Number
- NCT05941507
- Lead Sponsor
- LigaChem Biosciences, Inc.
- Brief Summary
This is a first-in-human, Phase 1/2 study to evaluate LCB84, a TROP2-directed antibody-drug conjugate, alone and in combination with an anti-PD-1 Ab, in dose escalation (Phase 1) followed by dose expansion (Phase 2).
The study population in dose escalation (Phase 1) consists of patients with advanced solid tumors refractory to standard of care, or for whom no standard of care exists. After the MTD and/or RP2D for single agent LCB84 is determined, dose escalation cohorts with select tumor types will be enrolled. Combination LCB84 and anti-PD-1 Ab will be evaluated in dose escalation after a minimum of 2 dose levels of single agent LCB84 have established DLT safety, to determine the MTD and/or RP2D of combination LCB84 and anti-PD-1 Ab, and to continue into dose expansion cohorts in select tumor types.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 300
-
Phase 1 Dose Escalation: histologically or cytologically confirmed advanced solid tumors refractory to standard of care treatment.
-
Phase 2 Dose Expansion*: select histologically or cytologically confirmed advanced solid tumors refractory to standard of care treatment.
*expansion cohort indications to be prioritized based on data from Phase 1 dose escalation.
-
Prior treatment with TROP2-directed therapy is permitted.
-
Measurable disease as defined by RECIST v1.1 or RANO-BM.
-
Willingness to provide archival tumor tissue when available or to undergo pre-treatment biopsy if not available.
-
Mandatory pre- and on-treatment biopsies for enrichment cohorts in Phase 1 dose escalation and Phase 2 expansion cohorts if deemed medically feasible and safe.
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
-
Adequate organ function as defined by:
- Absolute neutrophil count (ANC) ≥1.5 x 109/L (1500/µL), without colony-stimulating factor support for the past 14 days
- Platelets ≥100.0 x 109/L (100 000/µL)
- Hemoglobin ≥9.0 g/dL
- Aspartate aminotransferase (AST) ≤2.5 x ULN; alanine aminotransferase (ALT) ≤2.5 x ULN (AST, ALT ≤5 x ULN if liver metastases present)
Key
- Active or progressing central nervous system (CNS) metastases or any evidence of leptomeningeal disease.
Note: Patients with stable or treated CNS metastases may be eligible if all of the following criteria are met: 1) localized treatment for brain metastases completed at least 4 weeks prior to the first dose of study drug 2) no new or progressive neurologic symptoms and without need for immediate local therapy, steroids or anticonvulsants for symptom control (stable or decreasing steroid dose (a stable dose of ≤4 mg dexamethasone oral or equivalent) is permitted) 3) stable brain metastases for at least 1 month prior to screening (baseline) brain MRI.
- Persistent toxicities from previous systemic antineoplastic treatments >Grade 1, excluding alopecia and vitiligo.
- Systemic antineoplastic therapy (including antiestrogen therapy) within 5 half-lives or 4 weeks, whichever is shorter, prior to first dose of the study drug.
- Concomitant use of systemic steroids at dose of >10 mg of prednisone or its equivalent per day (exception for brain metastases, as described in exclusion criteria #1 above).
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description LCB84 monotherapy LCB84 IV infusion Q3W LCB84 + anti-PD-1 LCB84 IV infusion Q3W LCB84 + anti-PD-1 Anti-PD-1 monoclonal antibody IV infusion Q3W
- Primary Outcome Measures
Name Time Method Safety of LCB84 alone and LCB84 in combination with an anti-PD-1 Ab (Phase 1 and 2) Up to 48 months Incidence and severity of AEs and SAEs
Overall Survival (Phase 2) Up to 24 months Survival rates
Recommended Phase 2 Dose of LCB84 alone and LCB84 in combination with an anti-PD-1 Ab (Phase 1) Up to 24 months Based on tolerability, preliminary anti tumor activity, and pharmacokinetics
Duration of Response (Phase 2) Up to 24 months Assessed by RECIST 1.1, iRECIST, and RANO-BM
Time to Progression (Phase 2) Up to 24 months Assessed by RECIST 1.1, iRECIST, and RANO-BM
Progression Free Survival (Phase 2) Up to 24 months Assessed by RECIST 1.1, iRECIST, and RANO-BM
Objective Response Rate (Phase 2) Up to 24 months Assessed by RECIST 1.1, iRECIST, and RANO-BM
Clinical Benefit Rate (Phase 2) Up to 24 months Assessed by RECIST 1.1, iRECIST, and RANO-BM
- Secondary Outcome Measures
Name Time Method Plasma Concentrations of LCB84 (Phase 1 and 2) Up to 48 months Pharmacokinetic parameters will be determined from observed concentrations of LCB84
Evaluation of the immunogenicity of LCB84 (Phase 1 and 2) Up to 48 months Occurrence of ADA measured in serum at selected timepoints during the study
Objective Response Rate (Phase 1) Up to 24 months Assessed by RECIST 1.1, iRECIST, and RANO-BM
Duration of Response (Phase 1) Up to 24 months Assessed by RECIST 1.1, iRECIST, and RANO-BM
Time to Progression (Phase 1) Up to 24 months Assessed by RECIST 1.1, iRECIST, and RANO-BM
Progression Free Survival (Phase 1) Up to 24 months Assessed by RECIST 1.1, iRECIST, and RANO-BM
Trial Locations
- Locations (6)
Cedars Sinai Medical Center
🇺🇸Los Angeles, California, United States
Dana Farber Cancer Institute
🇺🇸Boston, Massachusetts, United States
Princess Margaret Cancer Centre
🇨🇦Toronto, Ontario, Canada
MD Anderson Cancer Center
🇺🇸Houston, Texas, United States
University of Michigan
🇺🇸Ann Arbor, Michigan, United States
Mary Crowley Cancer Research
🇺🇸Dallas, Texas, United States